Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis

被引:1
作者
Tafazzoli, Ali [1 ]
Chavan, Ameya [1 ]
Harty, Gerard [2 ]
Moller, Jorgen [3 ]
Wong, Schiffon L. [2 ]
机构
[1] Evidera, Evidence Synth Modeling & Commun, Bethesda, MD USA
[2] EMD Serono Inc, Global Res & Dev, Global Evidence & Value Dev, Billerica, MA USA
[3] Evidera, Evidence Synth Modeling & Commun, London, England
关键词
Cladribine tablets; Disease-modifying drug; Efficiency model; Infusion; Relapsing-remitting multiple sclerosis; ORAL CLADRIBINE; OPERATIONS; TIME;
D O I
10.1007/s12325-020-01426-7
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Introduction To develop a simulation model assessing the efficiency of using cladribine tablets versus infusion-based disease-modifying drugs (DMDs) for the treatment of relapsing-remitting multiple sclerosis (RRMS) from a facility perspective in the UK. Methods A scheduling algorithm was developed to simulate day-case admissions and calculate the mean changes to resource use and time burden for patients in a facility that transitions from infusion-based treatments to cladribine tablets over 1 year. Model inputs and assumptions were based on previous research and expert opinion. Model validation and quality checks were performed and additional scenario analyses were also conducted. Results The model successfully scheduled all infusion treatments in the base case and no patients were left off the schedule as a result of lack of capacity. Modeled base-case outcomes increased in future scenarios owing to a 35% increase in demand. The introduction of cladribine tablets reduced these impacts. Specifically, the difference in mean daily utilization was reduced in the future scenario from 13% to 3% as 8% of patients moved to cladribine tablets; annual administration costs decreased by 96% and annual time burden decreased by 90%. Results from additional scenarios showed the largest benefits from switching current infusion patients to cladribine tablets were realized in facilities having moderate to high resource utilization. Conclusions This model provides facility decision-makers the ability to assess the efficiency of using cladribine tablets rather than an infusion-based DMD. The simulation quantified the benefits gained from reducing the burden on facility resources by switching some patients with RRMS from infusion-based DMDs to cladribine tablets. Overall, modeled outcomes increased in future scenarios owing to an increase in demand, although the introduction of cladribine tablets reduced this impact.
引用
收藏
页码:3791 / 3806
页数:16
相关论文
共 29 条
[1]   Developing an efficient scheduling template of a chemotherapy treatment unit: A case study [J].
Ahmed, Z. ;
ElMekkawy, T. Y. ;
Bates, S. .
AUSTRALASIAN MEDICAL JOURNAL, 2011, 4 (10) :575-588
[2]   Modeling and simulation of oncology clinic operations in discrete event system specification [J].
Alvarado, Michelle M. ;
Cotton, Tanisha G. ;
Ntaimo, Lewis ;
Perez, Eduardo ;
Carpentier, William R. .
SIMULATION-TRANSACTIONS OF THE SOCIETY FOR MODELING AND SIMULATION INTERNATIONAL, 2018, 94 (02) :105-121
[3]   Prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal [J].
Andreou, A. P. ;
Trimboli, M. ;
Al-Kaisy, A. ;
Murphy, M. ;
Palmisani, S. ;
Fenech, C. ;
Smith, T. ;
Lambru, G. .
EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 (08) :1069-+
[4]   Greek NHS capacity constraints regarding intravenous treatment for rheumatoid arthritis patients [J].
Athanasakis, Kostas ;
Detsis, Marios ;
Souliotis, Kyriakos ;
Golna, Christina ;
Kyriopoulos, John .
RHEUMATOLOGY INTERNATIONAL, 2012, 32 (04) :921-926
[5]   Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches [J].
Berardi, Andrea ;
Siddiqui, Mohd Kashif ;
Treharne, Catrin ;
Harty, Gerard ;
Wong, Schiffon L. .
CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (08) :1371-1378
[6]  
Chen Zhi Ye, 2018, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V40, P158, DOI 10.3881/j.issn.1000-503X.2018.02.004
[7]   Early management of patients with medication-overuse headache: results from a multicentre clinical study [J].
Corbelli, I. ;
Sarchielli, P. ;
Eusebi, P. ;
Cupini, L. M. ;
Caproni, S. ;
Calabresi, P. .
EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 (08) :1027-1033
[8]  
De Cock E, 2018, MONITORING BURDEN MU
[9]   Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis [J].
Eagle, Tessa ;
Stuart, Fiona ;
Chua, Alicia S. ;
LaRussa, Allison ;
Leclaire, Kaitlynne ;
Cook, Sandra L. ;
Chitnis, Tanuja ;
Weiner, Howard L. ;
Glanz, Bonnie I. ;
Healy, Brian C. .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 18 :196-201
[10]   Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis [J].
Farber, Rebecca S. ;
Sand, Ilana K. .
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2015, 8 (05) :212-232